Surveys of Challenges in Access to Diagnostics and Treatment for Neuroendocrine Tumor (NET) Patients (SCAN) – Healthcare Quality Evaluation

Catherine Bouvier,1 Dirk Van Genechten,2 Teodora Kolarova,3 Mark McDonnell,4 Dermot O'Toole5, Harjit Singh6, Jie Chen7, James R. Howe8, Simron Singh9, Christine Rodien-Louv10, Simoney Leyden11, Sugandha Dureja12

1Neuroendocrine Cancer UK, Leamington Spa, UK, 2NET & MEN banker Belgium, Kortrijk, Belgium, 3INCA, Boston, US, 4NET Patient Network, Dublin, Ireland, 5National Centre for Neuroendocrine Tumours, St. Vincent’s University Hospital and Department of Clinical Medicine, St. James Hospital, Dublin, Ireland, 6Prince Court Medical Centre, Kuala Lumpur, Malaysia, 7First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, 8University of Iowa Cancer College of Medicine, Iowa City, IA, 9Gastrointestinal Cancer Centre, University of Toronto, Toronto, ON, 10APTED, Lyon, France, 11Neuroendocrine Cancer Australia, Bulk Range, VIC, AU, 12NEUTS India, New Delhi, India

INTRODUCTION

• Neuroendocrine tumors (NETs) are rare and complex neoplasms, affecting various organs, but most commonly the gastrointestinal tract.1
• NETs incidence and prevalence is increasing worldwide making it one of the fastest growing classes of cancer.2
• The International Neuroendocrine Cancer Alliance (INCA) consists of 26 patient advocacy and research groups and supports NET patients (and their families) by advocating on their behalf to improve diagnosis, care and research.

OBJECTIVE

• To assess global delivery of NET diagnostics and treatment in terms of:
  - Awareness
  - Availability
  - Quality
  - Affordability

• This analysis focused on the quality of global delivery of NET healthcare.

METHODS

• During Sept-Nov 2019, NET patients and healthcare professionals (HCPs) completed an online survey.
• The survey was disseminated via social media and NET patient groups’ and medical societies’ networks.
• The survey was available in 14 languages: Arabic, Bulgarian, English, German, Dutch/Flemish, French, Japanese, Hindi, Italian, Mandarin (Chinese), Portuguese, Russian, Spanish, and Swahili.
• On average, NET patients took 20 minutes and HCPs 11 minutes to complete the questionnaire.

RESULTS

Participant Characteristics

- There were 2795 respondents from 68 countries
- 436 HCPs of which medical oncologists comprised 24% (103/436)
- 2359 NET patients/carers: Europe 47% [1102/2359]; North America 31% [727/2359]; Asia 12% [280/2359]; Oceania 9% [200/2359]; South America & Africa 2% [50/2359].

Diagnosis

- Almost half (44% [1042/2359]) of patients were initially misdiagnosed.
- Almost half (46% [1077/2359]) of patients had stage IV NETs or had metastases at diagnosis.
- Mean time to diagnosis was 5 years, lower in Asia and higher in North America (t-test p<0.0001, Figure 1).

Healthcare Services

- Slightly over half of NET patients were consulted by a NET specialist in the past 12 months (P12M), with the highest rates in Europe and Oceania (All: 53% [1255/2359]; Europe: 61% [668/1102]; North America: 48% [350/727]; Asia: 43% [120/280]; Oceania: 53% [105/200], p<0.0001, Chi-squared, Figure 3).

Quality of Care

- The quality of healthcare provided was evaluated by NET patients at 3.5 and HCPs/medical oncologists at 3.3/3.1 (5-point Likert scale).

Recommendations

- The most common recommendation to improve NET diagnosis and management, given by medical oncologists, was "better access to NET experts/specialist centres" (75% [77/103]).

RESULTS continued

Healthcare Services

- Only one third of patients were reviewed by a multidisciplinary team in P12M, less in North America and Asia (All: 33% [769/2359]; Europe: 38% [415/1102]; North America: 29% [210/727]; Asia: 22% [62/280], Oceania: 39% [77/200], p<0.0001).

Quality of Care

- A medical oncologist was the most involved HCP in follow-up in 60% of NET patients, particularly in North America and Oceania (Europe 54% [593/1102] vs. North America 75% [548/727] vs. Asia 34% [95/280], vs. Oceania 75% [150/200] p<0.0001).

FUNDING AND DISCLOSURE

INCA would like to thank all its members as well as its partners: ENETS (European Neuroendocrine Tumor Society), NANTES (North American Neuroendocrine Tumor Society), APNETS (Asia-Pacific Neuroendocrine Tumor Society), CommNETs (Commonwealth Neuroendocrine Tumor Group), INETS (Japanese Neuroendocrine Tumor Society), CNTS (Chinese Neuroendocrine Tumor Society), UICC (Union for International Cancer Control), EURORDIS (European Organisation for Rare Diseases), NORD (National Organisation for Rare Diseases) and EECO (European Cancer Organisation) and many others for their instrumental support of this global effort.

ACKNOWLEDGEMENTS

This study was sponsored by Ipsen, ITM and Novartis.

The lead author has nothing to declare.

REFERENCES


CONCLUSIONS

• SCAN represents the biggest global compendium of data about NETs extant.
• Delayed NET diagnosis remains a global challenge.
• The delivery of healthcare to NET patients is in need of significant improvement globally to ensure proper and timely diagnosis and treatment.
• SCAN results will help drive forward optimal care and referral pathways to achieve the goal of earlier diagnosis.
• Improving access to NET specialists and multidisciplinary care should be a priority for healthcare systems.
• This survey further contributes to positioning NET research on an equal footing with other cancers of similar prevalence.